Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial

Judge, D. P., Gillmore, J. D., Alexander, K. M., Ambardekar, A. V., Cappelli, F., Fontana, M., García-Pavía, P., Grodin, J. L., Grogan, M., Hanna, M., Masri, A., Nativi-Nicolau, J., Obici, L., Hvitfeldt Poulsen, S., Sarswat, N., Shah, K., Soman, P., Lystig, T., Cao, X., … Maurer, M. S. (2024). Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial. Circulation. https://doi.org/10.1161/circulationaha.124.072771
Authors:
Daniel P Judge
Julian D Gillmore
Kevin M Alexander
Amrut V Ambardekar
Francesco Cappelli
Marianna Fontana
Pablo García-Pavía
Justin L Grodin
Martha Grogan
Mazen Hanna
Ahmad Masri
Jose Nativi-Nicolau
Laura Obici
Steen Hvitfeldt Poulsen
Nitasha Sarswat
Keyur Shah
Prem Soman
Ted Lystig
Xiaofan Cao
Kevin Wang
Maria Lucia Pecoraro
Jean-François Tamby
Leonid Katz
Uma Sinha
Jonathan C Fox
Mathew S Maurer
Affiliated Authors:
Mathew S Maurer
Author Keywords:
amyloidosis, familial
clinical trials as topic
exercise tolerance
hospitalization
mortality
quality of life
transthyretin-related heart failure
Publication Type:
Article
Unique ID:
10.1161/circulationaha.124.072771
PMID:
Journal:
Publication Date:
Data Source:
PubMed

Record Created: